MMC

A company accidentally spent $500 million on tokens. We're not making this up; fact is stranger than your AI agent's wildest hallucination. And they managed to spend it all in a single month because they hadn't set employee limits on Claude usage. In a si

In Part I of our AI x TechBio series we drew on 40+ interviews with senior pharma leaders and startup founders to break down what

Let's say you're the type of person who likes to bet. If you had a 2% chance of getting $200 billion (spread over 20 years), would you take it? The catch is that you'll have to spend $2 billion or so to place the bet, and you'll know if you won the bet on

We rely on recommendations everywhere. What to watch on Netflix, which song to listen to on Spotify, what to shop on Amazon, which Parisian hotel to stay at… and the list goes on. Without the curation of content, we would drown in data! But recommendation

An overview of how to overcome AI hallucination, context rot and amnesia by using Context Portability, Knowledge Graphs and Ontologies, and Search APIs

It was one of those dark November evenings in London - the kind where the rain lingers longer than it should. I'd just finished a long day in the office and made my way through the evening drizzle to meet Paulo and Bhasker (Baz), the founders of Condukt,

Discover how agentic AI startups are scaling in the enterprise - with data, pricing insights, and lessons from 70+ founders and practitioners.

Algorithmic trading has been the backbone of traditional finance for decades. From equities to foreign exchange and commodities, institutions have long relied on high performance execution strategies to optimise trade flow, reduce slippage, and ensure bes

We're thrilled to announce our latest investment: Atlas Metrics, a pioneering ESG data platform transforming how businesses approach sustainability reporting and compliance. As the lead investor in the €12.2 million Series A round, we're excited to share

Last year, we mapped out the landscape and dynamics of the "TechBio" space - companies blending cutting-edge technologies, computational methods, and data-driven, engineering-first approaches and applying it to biological research and drug development. No